Physician profile
Alan Ackermann
NPI 1194776054
$1,644.60
in general payments reported to CMS, 2019-2025
10 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $165 · 2022: $133 · 2023: $196 · 2024: $196 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $666.22 | 2019-2020 | |
| Heartflow, INC. | $516.68 | 2022-2025 | Ffrct |
| Cleerly, INC. | $102.48 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Astrazeneca Pharmaceuticals Lp | $90.00 | 2019 | |
| Cordis US Corp. | $86.97 | 2025 | Mynx Control Venous |
| Bayer Healthcare Pharmaceuticals INC. | $86.05 | 2025 | |
| Janssen Pharmaceuticals, INC | $44.78 | 2019 | |
| Abiomed | $20.73 | 2024 | Impella |
| Genzyme Corporation | $15.75 | 2023 | |
| Boston Scientific Corporation | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Ackermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.